Bal Pharma Ltd Financials
Company Logo

Bal Pharma Ltd Financial Statement

Bal Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue82.77
Operating Expense73.95
Net Profit5.61
Net Profit Margin6.78
Earning Per Share3.51
EBIDTA10.32
Effective Tax Rate-14.74

Bal Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual338.54
Operating Expenses Annual306.10
Operating Profit Annual35.79
Interest Annual15.24
Depreciation4.53
Net Profit Annual10.27
Tax Annual1.83

Bal Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning1.23
Cash Flow from Operations28.95
Cash Flow from Investing-18.43
Cash Flow from Financing-7.71
Cash Flow at the End4.04

Bal Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)10.63
PBIT Margin (%)8.13
PBT Margin (%)7.60
Net PROFIT Margin (%)3.03
Return On Networth / Equity (%)10.19
Return On Networth /Employed (%)11.63
Return On Assets (%)4.34
Total Debt / Equity (X)1.28
Asset Turnover Ratio (%)1.43

Bal Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual64.56
Total Current Assets Annual281.14
Non Current Assets Annual80.16
Total Shareholders Funds Annual105.58
Total Assets Annual361.30

Bal Pharma Ltd Earning Calls

EPS (INR)

Expected

3.41

Reported

3.40

Surprise

-0.29%

Dec 2024

EPS beaten by -0.29%

Sep 2024

EPS beaten by 10.00%

Jun 2024

EPS beaten by 0.00%

FAQS on Bal Pharma Ltd Financials

As of Jun 2, 2025, Bal Pharma Ltd has a market capitalization of 132.40 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Bal Pharma Ltd is not with a debt-to-equity ratio of 1.29.

In FY 2024 , Bal Pharma Ltd recorded a total revenue of approximately 302.50 Cr marking a significant milestone in the company's financial performance.

Bal Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and -0.0% annually, respectively..

Bal Pharma Ltd's current PE ratio is 16.97.

Bal Pharma Ltd's ROCE averaged 9.4% from the FY ending March 2023 to 2025, with a median of 9.4%. It peaked at 9.9% in March 2024, reflecting strong capital efficiency over the period..

Bal Pharma Ltd's latest EBIT is Rs. 22.58 Cr, surpassing the average EBIT of Rs. 22.46 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions